These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16105641)

  • 1. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 2. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 3. Levosimendan.
    Kamath SR; Jaykumar I; Matha S
    Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
    [No Abstract]   [Full Text] [Related]  

  • 4. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 5. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 7. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
    Asif M
    Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 12. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical support and surgery of the failing heart: levosimendan.
    Toller W; Knez I
    Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
    [No Abstract]   [Full Text] [Related]  

  • 14. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
    Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R
    Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
    Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan in cardiogenic shock: the magic drug for every patient?
    Smetana P; Geppert A
    Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.